Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis

Company Overview

Tonix Pharmaceuticals (NASDAQ:TNXP) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for central nervous system (CNS) disorders, immunological conditions, and rare diseases. Founded in 2007 and headquartered in New York, Tonix applies its translational research expertise to address unmet medical needs by advancing a diverse pipeline of product candidates through preclinical and clinical development stages. The company’s strategy centers on leveraging both pharmaceutical and vaccine platforms to deliver differentiated treatments across multiple therapeutic areas.

Tonix’s lead asset, TNX-102 SL, is a proprietary sublingual formulation of cyclobenzaprine designed to treat fibromyalgia and post-traumatic stress disorder (PTSD). The company has completed Phase 3 efficacy studies in fibromyalgia and is conducting trials in PTSD, aiming to offer patients an alternative to existing therapies with a convenient sublingual delivery system. In addition to its CNS portfolio, Tonix is developing TNX-801, a live vaccinia virus vaccine candidate for smallpox and monkeypox preparedness, and TNX-3500, an engineered oncolytic virus for potential cancer immunotherapy. These vaccine and immunotherapy programs stem from Tonix’s broader commitment to biodefense and immuno-oncology research.

Operating primarily in the United States, Tonix collaborates with governmental agencies, contract research organizations, and academic institutions to support its development activities and regulatory interactions. The company maintains facilities in New York and Massachusetts, where its multidisciplinary teams conduct translational research, process development, and clinical operations. Tonix’s leadership is helmed by CEO Seth Lederman, a neuroscientist and entrepreneur who cofounded the company and has overseen its expansion from a single-asset entity into a multifaceted biotech organization.

Looking ahead, Tonix aims to advance its pipeline through pivotal trials and regulatory submissions, while exploring strategic partnerships to accelerate commercialization and broaden geographic reach. By integrating novel formulation technologies and viral vector platforms, the company seeks to create value for patients and shareholders through targeted innovation in CNS, immunology, and rare disease therapeutics.

Key Stats

• Today's Range: $45.50 to $48.80
• 50-Day Range: $18.84 to $47.19
• 52-Week Range: $6.76 to $130.00
• Volume: 930,648 shs
• Average Volume: 994,092 shs
• Market Capitalization: $341.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $585.00
• Consensus Rating: Buy

Tonix Pharmaceuticals Stock Analysis - MarketRank™

Tonix Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 570th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tonix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tonix Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tonix Pharmaceuticals are expected to grow in the coming year, from ($1,762.50) to ($541.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tonix Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tonix Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tonix Pharmaceuticals has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.46% of the float of Tonix Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Tonix Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tonix Pharmaceuticals has recently increased by 7.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tonix Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Tonix Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.46% of the float of Tonix Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Tonix Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tonix Pharmaceuticals has recently increased by 7.08%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.38

News Sentiment

Tonix Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Tonix Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 53 people have searched for TNXP on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.

MarketBeat Follows

Only 34 people have added Tonix Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Tonix Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $86,200.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.03% of the stock of Tonix Pharmaceuticals is held by insiders.

Percentage Held by Institutions

82.26% of the stock of Tonix Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TNXP Stock Analysis - Frequently Asked Questions

How have TNXP shares performed this year?

Tonix Pharmaceuticals' stock was trading at $32.98 at the beginning of 2025. Since then, TNXP shares have increased by 41.7% and is now trading at $46.7250.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) released its quarterly earnings results on Monday, May, 12th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($3.23) by $0.39. The business had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.55 million. Tonix Pharmaceuticals had a negative net margin of 1,313.87% and a negative trailing twelve-month return on equity of 120.96%.

When did Tonix Pharmaceuticals' stock split?

Tonix Pharmaceuticals's stock reverse split on the morning of Wednesday, February 5th 2025.The 1-100 reverse split was announced on Monday, February 3rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tonix Pharmaceuticals investors own include Meta Platforms (META), Digital Turbine (APPS), NIO (NIO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNXP
• CIK: 1430306
• Web: www.tonixpharma.com
• Phone: (862) 799-8599
• Fax: 212-923-5700
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tonix Pharmaceuticals: $585.00
• High Price Target: $1,100.00
• Low Price Target: $70.00
• Potential Upside/Downside: +1,139.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1,963.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$130.04 million
• Net Margins: -1,313.87%
• Pretax Margin: -1,313.87%
• Return on Equity: -120.96%
• Return on Assets: -101.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.31
• Quick Ratio: 11.64

Sales & Book Value

• Annual Sales: $10.09 million
• Price / Sales: 34.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $31.82 per share
• Price / Book: 1.48

Miscellaneous

• Outstanding Shares: 7,360,000
• Free Float: 7,355,000
• Market Cap: $347.32 million
• Optionable: Not Optionable
• Beta: 2.05